A Physician-Initiated Phase II Clinical Trial of RE-01 (Ex Vivo Cultured Peripheral Blood Mononuclear Cells) for Therapeutic Angiogenesis in Non-Healing Lower Extremity Ulcers (PHOENIX-RE Trial)

未提供0 个研究点目标入组 10 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 招募中
入组人数: 10

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomized

入排标准

年龄范围: 18age old over 至 85age old under（—）
性别: All

入选标准

•Age of 18-85 years
•WIfI wound grade 1-2, size 0.5 cm^2<=,<=10 cm^2
•If there are ulcers on both limbs, the limb with the largest ulcer will be treated.
•Patients diagnosed with Buerger's disease or collagen diseases [including systemic sclerosis, systemic lupus erythematosus(SLE), dermatomyositis, rheumatoid arthritis, malignant rheumatoid arthritis, and various types of vasculitis (such as polyarteritis nodosa, microscopic polyangiitis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, lupus vasculitis, rheumatoid vasculitis, Takayasu arteritis, and sarcoid vasculitis, etc.)], and additionally diagnosed with ischemic ulcers caused by microvascular disorders, including vasculitis.
•Patients whose primary condition (the disease causing lower limb ischemia) is well-controlled.
•Patients in whom, despite 4 weeks of standard therapy for refractory ischemic lower extremity ulcers at the time of consent acquisition, the reduction rate of the largest ulcer area remains less than 50% compared to before treatment initiation, and closure by relatively simple procedures (such as suturing, skin grafting, or local flaps) is judged unlikely even if standard therapy is continued.
•Patients who cannot undergo revascularization surgery, or the maximum ulcer area reduction rate is less than 50% at 4 weeks after revascularization surgery.
•Patients who have not smoked within 3 months before consent acquisition and agree to refrain from smoking during the trial period.
•Provided written consent
•Comply with the protocol requirements

排除标准

•Ischemic ulcer or the ulcers due to Buerger's disease or collagen disease in the other limb, which is non healing or is predicted to have a major amputation
•Infected ulcer (WIfI infection grade 2<=), or uncontrollable infected ulcer with WIfI infection grade 1
•Ischemic ulcer with WIfI ischemia grade 3<=
•(However, if physiological tests of lower limb function cannot be performed due to pain, patients in whom a pulse sound is detected in the dorsalis pedis artery and posterior tibial artery by Doppler examination are eligible.)
•Heel ulcer
•Patients who are expected to require major amputation (at or above ankle disarticulation) during the clinical trial period due to progressive ulcers, gangrene, or sepsis.
•Patients who underwent minor amputation (at or above the metatarsophalangeal joint disarticulation and below the Lisfranc joint disarticulation) on the target limb during the screening period.
•Patients who have not passed at least four weeks since bypass surgery, angioplasty, or other surgical treatments on the target limb at the time of obtaining consent.
•Patients with resting pain, ulcers, or gangrene associated with lower limb ischemia caused by factors other than Buerger's disease or collagen diseases (such as spinal canal stenosis, osteoarthritis of the knee, lumbar spondylosis, arteriosclerosis obliterans, etc.).
•Ischemic ulcer due to peripheral arterial disease, which is diagnosed with MRI, angiography or CT scan during screening.
•Patients whose test culture of RE-01 cells during the screening period is expected to yield less than a total dose of 2*10^7cells per 200 mL of blood collected, or whose cell composition is predicted not to meet the release criteria.
•Patients who are predicted to be unable to endure at least five months of standard therapy from baseline.
•HbA1c >= 8.0%
•Severe systemic infection (CRP>5mg/dL)
•Hemoglobin level of less than 8g/dL
•Patients who are unable to stand even with a prosthesis due to prior major amputation on the contralateral limb.
•Patients with severe cardiac dysfunction (NYHA class 3 or 4, or left ventricular ejection fraction less than 35% on echocardiography at screening).
•Patients receiving drugs with angiogenesis inhibitory effects for the treatment of active diabetic proliferative retinopathy, etc.
•Patients with malignant tumors or within 5 years after curing malignancy (within 10 years for breast cancer).
•(However, patients with adequately treated non-melanoma skin cancer or cervical carcinoma in situ may participate in the trial.)
•Patients with hematological diseases such as hematologic malignancies, myeloproliferative disorders, or myelodysplastic syndromes.
•Patients with a history of hypersensitivity to the biological raw materials (human serum albumin, fetal bovine serum) used in the investigational product (RE-01).
•Pregnant or lactating women, women who may become pregnant and tested positive on a pregnancy test at screening, or men or women unwilling to use contraception during the clinical trial period.
•Patients who test positive for HIV, active HBV, HCV, HTLV, or syphilis during screening examinations.
•Patients who have previously received the investigational product (RE-01) or its predecessor (MNC-QQ cells).
•Patients who are considered to have a life expectancy of less than one year due to comorbidities, etc.
•Patients with comorbidities such as dementia that are deemed likely to significantly affect the evaluation of the efficacy and safety of the investigational product.
•Patients who participated in another clinical trial within 90 days prior to obtaining consent (patients who did not receive investigational drugs may participate).
•Other patients deemed inappropriate for this trial by the principal investigator or other responsible physicians.

研究者

发起方

未提供

相似试验

招募中

不适用

Investigator-Initiated Phase II Clinical Trial of MA-5 for Mitochondrial Disease An Exploratory, Investigator-Initiated Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MA-5 in Patients with Mitochondrial Disease and Hearing LossMitochondrial disease with hearing loss

jRCT203125050515

招募中

不适用

A Phase I/II exploratory clinical trial to evaluate the efficacy and safety of RBBM-S1 in patients requiring lumbar interbody fusion for degenerative lumbar disease, in comparison with the standard treatment of autologous bone grafting.lumbar stenosis, spondylolisthesis, spondylolysis, scoliosis, instability, disc disease

jRCT203125056936

招募中

不适用

A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal CancerMetastatic Colorectal Neoplasms,Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer

jRCT203126004768

招募中

不适用

A Phase II Investigator-Initiated Clinical Trial Evaluating the Efficacy and Safety of Combination Therapy with a PAI-1 Inhibitor (TM5614) and Immune Checkpoint Inhibitor Consolidation Therapy following Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (TM-Alliance study) (TM-Alliance study)non-small cell lung cancer

jRCT206126000127

招募中

1 期

A phase 1, controlled, open-label, single dose, dose-escalation, clinical proof-of-concept study of MRI enhanced with ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in patients with brain amyloid deposits as demonstrated by amyloid PETAlzheimer's disease

2024-520078-36-00Alzeca Biosciences Inc.18